ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The company is headquartered in San Diego, California and currently employs 540 full-time employees. The company went IPO on 2004-05-27. The firm is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The Company’s portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address significant unmet needs in CNS disorders and rare diseases. The Company’s pipeline includes NUPLAZID, Trofinetide, ACP-204 and Antisense Oligonucleotide (ASO) Programs. Its NUPLAZID is a treatment for Parkinson’s Disease Psychosis. Trofinetide is a treatment for Rett Syndrome. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its ACP-204 is a treatment for Alzheimer’s Disease Psychosis.